Comparative Pharmacology
Head-to-head clinical analysis: ALESSE versus ESTERIFIED ESTROGENS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALESSE versus ESTERIFIED ESTROGENS.
ALESSE vs ESTERIFIED ESTROGENS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, promoting proliferation of endometrial and breast epithelium, and exerting effects on bone, cardiovascular, and central nervous systems.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
1.25 mg orally once daily for 21 days, followed by a 7-day drug-free period per cycle. Adjust based on response.
None Documented
None Documented
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life is approximately 10-24 hours, reflecting the prolonged activity of conjugated metabolites and enterohepatic cycling. Steady-state is achieved within 3-5 days.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Approximately 60-80% of the dose is excreted in the urine (as glucuronide and sulfate conjugates), with the remaining 20-40% excreted in feces via bile.
Category C
Category C
Estrogen/Progestin Combination Contraceptive
Estrogen